Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (Nasdaq: BEAM) reported Q4 and full-year 2025 results, noted a strengthened balance sheet with $1.25B in cash and marketable securities, and announced a new liver-targeted program BEAM-304 for phenylketonuria (PKU) with an IND expected in 2026.
Beam secured a $500M senior secured facility with Sixth Street, expects a minimum $200M draw, and reiterated plans for a potential BLA submission for risto-cel as early as year-end 2026 and BEAM-302 pivotal next steps in Q1 2026.
Beam Therapeutics (Nasdaq: BEAM) secured a $500 million senior secured credit facility with Sixth Street to support the anticipated commercial launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease. $100 million funded at close; up to $300 million tied to clinical, regulatory, and commercial milestones; plus a $100 million option. The seven-year facility matures in early 2033, bears ~10% annual interest, requires no scheduled amortization, is secured by first‑priority liens on substantially all assets, and includes mandatory prepayments from certain extraordinary proceeds.
Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.
The live webcast will be available in the investor section of the company's website and will be archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported Q3 2025 results and clinical progress. Cash, cash equivalents and marketable securities were $1.1 billion as of Sept 30, 2025, with a cash runway expected into 2028. The company advanced multiple programs: expanded dosing in Part A and dose escalation in Part B of BEAM-302 (AATD), first patient dosed in Part B, BEAM-103 first healthy volunteer dosed, and BEACON (BEAM-101) data accepted for ASH presentation. BEAM-101 received RMAT designation. Q3 R&D was $109.8M, G&A $26.7M, and net loss $112.7M (‑$1.10/sh).
Beam Therapeutics (Nasdaq: BEAM) outlined 2026 strategic priorities for its liver-targeted genetic disease and hematology franchises and announced an extended operating runway. Key regulatory and clinical milestones include FDA alignment on a potential accelerated approval pathway for BEAM-302 in AATD based on 12-month biomarkers, a planned BLA submission for risto-cel as early as year-end 2026, and an expected disclosure of a new liver-targeted program in H1 2026. Beam estimates $1.25 billion in cash and marketable securities as of Dec 31, 2025, supporting operations into 2029.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT in San Francisco.
The presentation will be available via a live webcast on the company's investor website at www.beamtx.com and the webcast will be archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported updated BEACON Phase 1/2 data for ristoglogene autogetemcel (risto-cel) in 31 adults and adolescents with severe sickle cell disease (data cut-off Aug 6, 2025; follow-up 0.3–20.4 months).
Key results: mean HbF >60%, mean HbS <40%, durable editing (peripheral editing 67.4% at Month 6; 72.8% at Month 12), median 1 stem cell collection cycle (median 3 total collection days), median neutrophil engraftment 17.5 days and platelet engraftment 19 days, and no investigator-reported severe VOCs post-engraftment. One patient died 4 months post-infusion; investigator attributed death likely to busulfan conditioning.
Beam Therapeutics (Nasdaq: BEAM) announced that company management will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 3:30 p.m. GMT in London.
The event will be available via a live webcast in the company's investor section at www.beamtx.com and the webcast will be archived for 60 days following the presentation.
Beam Therapeutics (Nasdaq: BEAM) will present updated safety and efficacy data from the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease at the 67th American Society of Hematology Annual Meeting, December 6-9, 2025 in Orlando.
Two presentations: a poster on Dec 6, 2025, 5:30–7:30 p.m. ET (Abstract 2532) reporting robust fetal hemoglobin induction and improvements in anemia and hemolysis; and an oral presentation on Dec 8, 2025, 5:30–5:45 p.m. ET (Abstract 1049) on CD34+ mobilization, collection, and safety comparing fixed-dose versus weight-based plerixafor dosing. Presenters: Ashish Gupta, M.D., MPH, and Haydar Frangoul, M.D.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines through base editing, has announced its participation in three major investor conferences in September 2025.
The company's management will engage in fireside chats at Citi's 2025 Biopharma Back to School Conference (September 3), the 2025 Wells Fargo Healthcare Conference (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 8). All presentations will be available via webcast on the company's investor relations website for 60 days following each event.